Evrys Bio, LLC

Confidential Unaudited Financial Statements STATEMENT OF INCOME

	For the quarter ended March 31,			
	 2020		2019	
Revenues Total Revenue *	\$ 64,358	\$	181,082	
Operating Expenses				
Research and Development	\$ 444,043	\$	339,361	
General and Administrative	\$ 351,269	\$	198,266	
Total Operating Expenses	\$ 795,312	\$	537,627	
Net Income (Loss)	\$ (730,954)	\$	(356,545)	

^{*} We have a \$90,000 tax credit to be sold in 2020.

Evrys Bio, LLC

Confidential Unaudited Financial Statements STATEMENT OF FINANCIAL POSITION

	March 31, 2020		December 31, 2019	
Assets				_
Cash	\$	671,908	\$	992,037
Accounts Receivable	\$	138,903	\$	383,788
Prepaid services *	\$ \$ \$	848,000	\$	655,933
Total current assets	\$	1,658,812	\$	2,031,758
Property and equipment				
Total Assets	\$	1,658,812	\$	2,031,758
Liabilities and members' equity				
Current Liabilities				
Accounts Payable	\$	231,124	\$	172,938
Other Current Liabilities	\$	94,871	\$	195,049
Total Liabilities	\$	325,994	\$	367,986
Members' Equity				
Members' Equity	\$	2,063,771	\$	2,858,901
Net Income	\$ \$	(730,954)	\$	(1,195,129)
Total Member's equity (deficit)	\$	1,332,818	\$	1,663,772
Total Liabilities and members' equity (deficit)	\$	1,658,812	\$	2,031,758

^{*} Prepaid services reference services in exchange for equity investment in Evrys Bio.
This will be drawn down as the services are completed.